微小RNA及其他非编码RNA在慢性淋巴细胞白血病发病机制中的作用
The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia.
作者信息
Calin George A, Pekarsky Yuri, Croce Carlo M
机构信息
Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Wiseman Hall Room 385K, 400 12th Avenue, Ohio State University, Columbus, OH 43210, USA.
出版信息
Best Pract Res Clin Haematol. 2007 Sep;20(3):425-37. doi: 10.1016/j.beha.2007.02.003.
New findings support the view that chronic lymphocytic leukemia (CLL) is a genetic disease in which the main alterations occur in a new class of genes named microRNAs (miRNAs). Cases with good prognostic features typically are characterized by miRNA down-regulation of genes miR-15a and miR-16-1, located at 13q14.3. Both microRNAs negatively regulate BCL2 at a post-transcriptional level. On the other hand, in CLL cases that use unmutated immunoglobulin heavy-chain variable-region genes (IgV(H)) or have high-level expression of the 70-kD zeta-associated protein (ZAP-70) have high levels of TCL1 due to low-level expression of miR-29 and miR-181, which directly target this oncogene. Conceivably, these miRNAs might be used to target BCL2 or TCL1 for therapy of this disease.
新发现支持这样一种观点，即慢性淋巴细胞白血病（CLL）是一种遗传性疾病，其主要改变发生在一类名为微小RNA（miRNA）的新基因中。具有良好预后特征的病例通常表现为位于13q14.3的miR-15a和miR-16-1基因的miRNA下调。这两种微小RNA在转录后水平上对BCL2起负调控作用。另一方面，在使用未突变免疫球蛋白重链可变区基因（IgV(H)）或70-kD ζ相关蛋白（ZAP-70）高表达的CLL病例中，由于直接靶向该癌基因的miR-29和miR-181低表达，TCL1水平较高。可以想象，这些微小RNA可用于靶向BCL2或TCL1来治疗这种疾病。
Zotero 插件